Scaling Up Viral Vector Harvest with Ease and Regulatory Compliance

The rapid rise of gene therapy using AAV and LV vectors has created urgent demand for scalable, high-performance bioproduction. A major challenge is cell lysis—where simplicity, compliance, and efficiency must align. With Triton™ X-100 under EU REACH restriction, a next-gen solution is needed. This paper explores how J.T.Baker® Cell Lysis Solution delivers ease of use, regulatory compliance, and process performance with low viscosity, a concentrated format, and endonuclease compatibility.